NCT03108794

Brief Summary

CR-HepB registry started in June 30,2012 to collect HBV cases from general hospitals or specialized hospitals for infectious diseases in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. The main criteria for registration is HBsAg-positivity more than 6 months, and these patients will receive followed-up visits every three to six months.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2012

Longer than P75 for all trials

Geographic Reach
1 country

45 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 30, 2012

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

April 6, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 11, 2017

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

November 6, 2017

Status Verified

November 1, 2017

Enrollment Period

10.5 years

First QC Date

April 6, 2017

Last Update Submit

November 2, 2017

Conditions

Keywords

hepatitis B,registry,cirrhosis, HCC

Outcome Measures

Primary Outcomes (1)

  • Rate of liver-related events after antiviral therapy

    Rates of cirrhosis,decompensation and hepatocellular carcinoma with or without antiviral therapy

    10 years

Secondary Outcomes (2)

  • The HBV DNA undetectable rate with or without antiviral therapy

    10 years

  • HBeAg loss and seroconversion rates with or without antiviral therapy

    10 years

Other Outcomes (2)

  • HBsAg loss and seroconversion rates with or without antiviral therapy

    10 years

  • Quality of life

    10 years

Study Arms (7)

Immune tolerance phase

Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.

HBeAg positive CHB

HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.

HBeAg negative CHB

HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.

Inactive HBsAg carriers

Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.

Compensated cirrhosis

Diagnosis of compensated cirrhosis can be made if one of the following criteria was met: 1. by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4. 2. endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension. 3. at least 2 features of cirrhosis: 1. irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness \> 4.0cm or \> 5 rib units) on ultrasound ,CT or MRI; 2. PLT\<100×109/L without other causes; 3. Serum album in\<35 g/L or INR\>1.3 or PT prolongs\>3s; 4. LSM\>13 kpa (ALT\<5×ULN).

Decompensated cirrhosis

Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.

Hepatocellular carcinoma

Diagnosis of hepatocellular carcinoma(HCC)can be established when one of the following one of the following 2 criteria:(1)in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or(2)histological evidence of HCC.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The registry is a multicentre and observational study enrolling patients with hepatitis B across China. The main criteria for patients registration within the system was HBsAg-positivity over a continuous six months. The core exclusion criteria are: 1) HCC patients for their treatment mainly depends on surgical operation and interventional therapy, but not the antiviral therapy; 2) patients who are unable or unwilling to provide informed consent. All potential subjects meeting enrollment criteria are offered the opportunity to participate.

You may qualify if:

  • HBsAg-positivity over a continuous six months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (45)

Beijing Ditan Hospital

Beijing, Beijing Municipality, 100015, China

RECRUITING

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100032, China

RECRUITING

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

RECRUITING

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

RECRUITING

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100050, China

RECRUITING

Beijing Youan Hospital

Beijing, Beijing Municipality, 100069, China

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400010, China

RECRUITING

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

RECRUITING

Lanzhou University Second Hospital

Lanzhou, Gansu, 730030, China

RECRUITING

The First Hospital of Lanzhou University

Lanzhou, Gansu, 730099, China

RECRUITING

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China

RECRUITING

The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, 550004, China

RECRUITING

Guizhou provincial people's hospital

Guiyang, Guizhou, China

RECRUITING

Hainan General Hospital

Haikou, Hainan, 570311, China

RECRUITING

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

RECRUITING

The Fifth Hospital of Shijiazhuang

Shijiazhuang, Hebei, 050021, China

RECRUITING

The Third Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050051, China

RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China

RECRUITING

Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

RECRUITING

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

RECRUITING

Hunan Provincial People's Hospital

Changsha, Hunan, 410005, China

RECRUITING

Xiangya Hospital Central South University

Changsha, Hunan, 410008, China

RECRUITING

Infectious Disease Hospital of Wuhai

Wuhai, Inner Mongolia, 016099, China

RECRUITING

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221006, China

RECRUITING

First Hospital of Jilin University

Changchun, Jilin, 130021, China

RECRUITING

The Affiliated Hospital of Yanbian University

Yanbian, Jilin, 133000, China

RECRUITING

Shengjing Hospital of China Medical University

Shenyang, Liaoning, 110004, China

RECRUITING

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 70004, China

RECRUITING

The Second Hospital of Shandong University

Jinan, Shandong, 250033, China

RECRUITING

Affiliated Hospital of Weifang Medical University

Weifang, Shandong, 261031, China

RECRUITING

Shanghai Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

Shanghai Public Health Clinical Center

Shanghai, Shanghai Municipality, 201508, China

RECRUITING

The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

RECRUITING

Taiyuan No.3 Hospital

Taiyuan, Shanxi, 030012, China

RECRUITING

First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710061, China

RECRUITING

Yanan University Affiliated Hospital

Yanan, Shanxi, 716000, China

RECRUITING

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

RECRUITING

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646099, China

RECRUITING

Affiliated Hospital, Logistics University of People's Armed Police Force

Tianjin, Tianjin Municipality, 300163, China

RECRUITING

Tianjin Third Central Hospital

Tianjin, Tianjin Municipality, 610041, China

RECRUITING

People's Hospital of Changji Hui Autonomous Prefecture,Xinjiang

Changji, Xinjiang, 831118, China

RECRUITING

First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830054, China

RECRUITING

Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital

Ürümqi, Xinjiang, 830099, China

RECRUITING

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650032, China

RECRUITING

Xixi Hospital of Hangzhou

Hangzhou, Zhejiang, 310023, China

RECRUITING

Related Publications (3)

  • You H, Kong Y, Hou J, Wei L, Zhang Y, Niu J, Han T, Ou X, Dou X, Shang J, Tang H, Xie Q, Ding H, Ren H, Xu X, Xie W, Liu X, Xu Y, Li Y, Li J, Chow SC, Zhuang H, Jia J. Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. Sci Rep. 2016 Nov 28;6:37498. doi: 10.1038/srep37498.

    PMID: 27892487BACKGROUND
  • Zhang Y, Wang Y, Jiao S, Li S, Liu X, Li T, Qu Y. Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. BMC Infect Dis. 2025 Nov 21;25(1):1635. doi: 10.1186/s12879-025-12016-9.

  • Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H, Jia J; CR-Hepb Study Group, Beijing, China. China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health. 2020 Mar;48(2):233-239. doi: 10.1177/1403494818772188. Epub 2018 May 1.

MeSH Terms

Conditions

Hepatitis B, ChronicFibrosis

Condition Hierarchy (Ancestors)

Hepatitis BBlood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitis, ChronicHepatitisLiver DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jidong Jia, Doctor

    Beijing Friendship Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Liver Research Center

Study Record Dates

First Submitted

April 6, 2017

First Posted

April 11, 2017

Study Start

June 30, 2012

Primary Completion

December 31, 2022

Study Completion

December 31, 2025

Last Updated

November 6, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share

Locations